Advertisement
Screener

Cue Biopharma, Inc. (CUE) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

2.5 / 5 stars · 30/60 Roast Me

Cue Biopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

Cue Biopharma, Inc. (CUE) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $14.98 per share as of 2021-08-20, per its 10-K filed 2023-03-21.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2023-03-21

  • 2021-08-20: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $14.98.
  • 2020-01-21: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $7.83.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
2021-08-20$14.98
10-K · filed 2023-03-21
2020-01-21$7.83
10-K · filed 2022-03-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
MACROGENICS INC (MGNX)United States$0.242B-20.11
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33
Cartesian Therapeutics, Inc. (RNAC)United States$0.231B-2.04
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Keros Therapeutics, Inc. (KROS)United States$0.229B-2.55